Sobi’s Acquisition of Dova

On September 30, 2019, Swedish Orphan Biovitrum AB (publ) (“Sobi”), an international biopharmaceutical company that provides access to innovative therapies for people affected by rare diseases, announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (“Dova”), maker of Doptelet, used for the treatment of thrombocytopenia. The transaction is valued at up $915 million on a fully diluted basis. Cravath is representing Sobi in connection with the transaction.

The Cravath team includes senior attorney Brittain A. Rogers and associates Jin-Kyu Baek, Nathan H. Trunnell, Michael P. E. Dooley and Ashkan Towhid on M&A matters; associate Andrew T. Davis on tax matters; partner Eric W. Hilfers, associate Brendon J. Rivard on executive compensation and benefits matters; partner David J. Kappos, specialist attorney Anthony N. Magistrale and associate Carys A. Johnson on intellectual property matters; partner Matthew Morreale on environmental matters; of counsel Christopher J. Kelly on financing matters; and senior attorney Jesse M. Weiss on antitrust matters.